-
1
-
-
0003266285
-
THRIVE IV: an open-label, pilot study of the treatment of pulmonary embolism with the oral direct thrombin inhibitor ximelagatran
-
Wahlander K, Lapidus L, Olsson C. THRIVE IV: an open-label, pilot study of the treatment of pulmonary embolism with the oral direct thrombin inhibitor ximelagatran. Blood 2001; 98: 268A-269.
-
(2001)
Blood
, vol.98
-
-
Wahlander, K.1
Lapidus, L.2
Olsson, C.3
-
2
-
-
0141636587
-
A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I
-
Eriksson H, Wahlander K, Gustafsson D etal. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J. Thromb. Haemost. 2003; 1: 41-47.
-
(2003)
J. Thromb. Haemost.
, vol.1
, pp. 41-47
-
-
Eriksson, H.1
Wahlander, K.2
Gustafsson, D.3
-
3
-
-
57849143295
-
Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran
-
Agnelli G, Eriksson BI, Cohen AT etal. Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran. Thromb. Res. 2009; 123: 488-497.
-
(2009)
Thromb. Res.
, vol.123
, pp. 488-497
-
-
Agnelli, G.1
Eriksson, B.I.2
Cohen, A.T.3
-
4
-
-
0038185371
-
Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study
-
Petersen P, Grind M, Adler J, Investigators SI. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. J. Am. Coll. Cardiol. 2003; 41: 1445-1451.
-
(2003)
J. Am. Coll. Cardiol.
, vol.41
, pp. 1445-1451
-
-
Petersen, P.1
Grind, M.2
Adler, J.3
Investigators, S.I.4
-
5
-
-
33746287448
-
Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran
-
Harenberg J, Jorg I, Weiss C. Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran. Int. J. Toxicol. 2006; 25: 165-169.
-
(2006)
Int. J. Toxicol.
, vol.25
, pp. 165-169
-
-
Harenberg, J.1
Jorg, I.2
Weiss, C.3
-
6
-
-
70349306707
-
Dabigatran versus warfarin in patients with atrial fibrillation
-
Connolly SJ, Ezekowitz MD, Yusuf S etal. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2009; 361: 1139-1151.
-
(2009)
N. Engl. J. Med.
, vol.361
, pp. 1139-1151
-
-
Connolly, S.J.1
Ezekowitz, M.D.2
Yusuf, S.3
-
8
-
-
80052592404
-
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
-
Patel MR, Mahaffey KW, Garg J etal. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 2011; 365: 883-891.
-
(2011)
N. Engl. J. Med.
, vol.365
, pp. 883-891
-
-
Patel, M.R.1
Mahaffey, K.W.2
Garg, J.3
-
9
-
-
80052825103
-
Apixaban versus warfarin in patients with atrial fibrillation
-
Granger CB, Alexander JH, McMurray JJ etal. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2011; 365: 981-992.
-
(2011)
N. Engl. J. Med.
, vol.365
, pp. 981-992
-
-
Granger, C.B.1
Alexander, J.H.2
McMurray, J.J.3
-
10
-
-
71849117615
-
Dabigatran versus warfarin in the treatment of acute venous thromboembolism
-
Schulman S, Kearon C, Kakkar AK etal. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N. Engl. J. Med. 2009; 361: 2342-2352.
-
(2009)
N. Engl. J. Med.
, vol.361
, pp. 2342-2352
-
-
Schulman, S.1
Kearon, C.2
Kakkar, A.K.3
-
12
-
-
84859385808
-
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism
-
Investigators E-P, Buller HR, Prins MH etal. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N. Engl. J. Med. 2012; 366: 1287-1297.
-
(2012)
N. Engl. J. Med.
, vol.366
, pp. 1287-1297
-
-
Investigators, E.-P.1
Buller, H.R.2
Prins, M.H.3
-
13
-
-
84880327613
-
Oral apixaban for the treatment of acute venous thromboembolism
-
Agnelli G, Buller HR, Cohen A etal. Oral apixaban for the treatment of acute venous thromboembolism. N. Engl. J. Med. 2013; 369: 799-808.
-
(2013)
N. Engl. J. Med.
, vol.369
, pp. 799-808
-
-
Agnelli, G.1
Buller, H.R.2
Cohen, A.3
-
14
-
-
84874003257
-
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism
-
Schulman S, Kearon C, Kakkar AK etal. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N. Engl. J. Med. 2013; 368: 709-718.
-
(2013)
N. Engl. J. Med.
, vol.368
, pp. 709-718
-
-
Schulman, S.1
Kearon, C.2
Kakkar, A.K.3
-
15
-
-
84873596181
-
Apixaban for extended treatment of venous thromboembolism
-
Agnelli G, Buller HR, Cohen A etal. Apixaban for extended treatment of venous thromboembolism. N. Engl. J. Med. 2013; 368: 699-708.
-
(2013)
N. Engl. J. Med.
, vol.368
, pp. 699-708
-
-
Agnelli, G.1
Buller, H.R.2
Cohen, A.3
-
16
-
-
35348879239
-
Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO study)
-
Ezekowitz MD, Reilly PA, Nehmiz G etal. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO study). Am. J. Cardiol. 2007; 100: 1419-1426.
-
(2007)
Am. J. Cardiol.
, vol.100
, pp. 1419-1426
-
-
Ezekowitz, M.D.1
Reilly, P.A.2
Nehmiz, G.3
-
17
-
-
84889643720
-
-
CARM. [Cited 29 Oct 2013.] Available from
-
CARM. [Cited 29 Oct 2013.] Available from URL: http://www.medsafe.govt.nz/consumers/Safety-of-Medicines/UpdateOnPradaxa.asp
-
-
-
-
18
-
-
84889640667
-
-
ADRAC. [Cited 29 Oct 2013.] Available from
-
ADRAC. [Cited 29 Oct 2013.] Available from URL: http://www.tga.gov.au/safety/alerts-medicine-dabigatran-111005.htm#ae-reports
-
-
-
-
20
-
-
84889635153
-
-
Early reversal with prothrombin complex concentrate in vitamin K antagonist-treated patients with severe haemorrhage is associated with decreased mortality. ISTH Abstracts. Amsterdam
-
Vigué B. Early reversal with prothrombin complex concentrate in vitamin K antagonist-treated patients with severe haemorrhage is associated with decreased mortality. ISTH Abstracts. Amsterdam, 2013.
-
(2013)
-
-
Vigué, B.1
-
21
-
-
80053571188
-
Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects
-
Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573-1579.
-
(2011)
Circulation
, vol.124
, pp. 1573-1579
-
-
Eerenberg, E.S.1
Kamphuisen, P.W.2
Sijpkens, M.K.3
Meijers, J.C.4
Buller, H.R.5
Levi, M.6
-
22
-
-
84858755308
-
The successful reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat tail bleeding model do not correlate with ex vivo markers of anticoagulation
-
van Ryn J, Schurer J, Kink-Eiband M, Clemens A. The successful reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat tail bleeding model do not correlate with ex vivo markers of anticoagulation. Blood 2011; 118: 1004-04.
-
(2011)
Blood
, vol.118
, pp. 1004-1004
-
-
van Ryn, J.1
Schurer, J.2
Kink-Eiband, M.3
Clemens, A.4
-
23
-
-
84889670630
-
-
Effects of three-factor and four-factor prothrombin complex concentrates on the pharmacodynamics of rivaroxaban. ISTH Abstracts. OC 36.5.
-
Levi M. Effects of three-factor and four-factor prothrombin complex concentrates on the pharmacodynamics of rivaroxaban. ISTH Abstracts. 2013: OC 36.5.
-
(2013)
-
-
Levi, M.1
-
24
-
-
84864370719
-
Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers
-
Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb. Haemost. 2012; 108: 217-224.
-
(2012)
Thromb. Haemost.
, vol.108
, pp. 217-224
-
-
Marlu, R.1
Hodaj, E.2
Paris, A.3
Albaladejo, P.4
Cracowski, J.L.5
Pernod, G.6
-
25
-
-
84655176578
-
Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model
-
Godier A, Miclot A, Le Bonniec B etal. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 2012; 116: 94-102.
-
(2012)
Anesthesiology
, vol.116
, pp. 94-102
-
-
Godier, A.1
Miclot, A.2
Le Bonniec, B.3
-
26
-
-
84886258579
-
Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis
-
Martin AC, Le Bonniec B, Fischer AM etal. Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis. Int. J. Cardiol. 2013; 168: 4228-4233.
-
(2013)
Int. J. Cardiol.
, vol.168
, pp. 4228-4233
-
-
Martin, A.C.1
Le Bonniec, B.2
Fischer, A.M.3
-
27
-
-
84874256149
-
Abstracts from the emerging science series, June 20, 2012
-
Escolar E. Abstracts from the emerging science series, June 20, 2012. Circulation 2012; 126: 520-521.
-
(2012)
Circulation
, vol.126
, pp. 520-521
-
-
Escolar, E.1
-
28
-
-
67849124919
-
Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant Factor VIIa or activated prothrombin complex concentrate (abstract 0370)
-
Abstract 0370.
-
van Ryn J, Ruehl D, Priepke H etal. Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant Factor VIIa or activated prothrombin complex concentrate (abstract 0370). Haematologica 2008; 93: Abstract 0370.
-
(2008)
Haematologica
, vol.93
-
-
van Ryn, J.1
Ruehl, D.2
Priepke, H.3
-
29
-
-
84856214360
-
Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran
-
Zhou W, Schwarting S, Illanes S etal. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011; 42: 3594-3599.
-
(2011)
Stroke
, vol.42
, pp. 3594-3599
-
-
Zhou, W.1
Schwarting, S.2
Illanes, S.3
-
30
-
-
84879549154
-
Potential of activated prothrombin complex concentrate and activated factor VII to reverse the anticoagulant effects of rivaroxaban in primates
-
ASH Annual Meeting Abstracts, 112: 3825.
-
Gruber A, Marzec UM, Buetehorn U, Hanson S, Perzborn E. Potential of activated prothrombin complex concentrate and activated factor VII to reverse the anticoagulant effects of rivaroxaban in primates. ASH Annual Meeting Abstracts 2008; 112: 3825.
-
(2008)
-
-
Gruber, A.1
Marzec, U.M.2
Buetehorn, U.3
Hanson, S.4
Perzborn, E.5
-
31
-
-
84865793090
-
Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate
-
Lambourne MD, Eltringham-Smith LJ, Gataiance S, Arnold DM, Crowther MA, Sheffield WP. Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate. J. Thromb. Haemost. 2012; 10: 1830-1840.
-
(2012)
J. Thromb. Haemost.
, vol.10
, pp. 1830-1840
-
-
Lambourne, M.D.1
Eltringham-Smith, L.J.2
Gataiance, S.3
Arnold, D.M.4
Crowther, M.A.5
Sheffield, W.P.6
-
32
-
-
84870776429
-
Successful removal of dabigatran in flowing blood with an activated charcoal hemoperfusion column in an in vitro test system
-
Van Ryn J, Neubauer M, Flieg R etal. Successful removal of dabigatran in flowing blood with an activated charcoal hemoperfusion column in an in vitro test system. Haematol. 2010; 95: 293-93.
-
(2010)
Haematol.
, vol.95
, pp. 293-293
-
-
Van Ryn, J.1
Neubauer, M.2
Flieg, R.3
-
33
-
-
84875926001
-
Effective elimination of dabigatran by haemodialysis A phase I single-centre study in patients with end-stage renal disease
-
Khadzhynov D, Wagner F, Formella S etal. Effective elimination of dabigatran by haemodialysis A phase I single-centre study in patients with end-stage renal disease. Thromb. Haemost. 2013; 109: 596-605.
-
(2013)
Thromb. Haemost.
, vol.109
, pp. 596-605
-
-
Khadzhynov, D.1
Wagner, F.2
Formella, S.3
-
34
-
-
84861975957
-
An antibody selective to dabigatran safely neutralizes both dabigatran-induced anticoagulant and bleeding activity in in vitro and in vivo models
-
Van Ryn J, Litzenburger T, Waterman A etal. An antibody selective to dabigatran safely neutralizes both dabigatran-induced anticoagulant and bleeding activity in in vitro and in vivo models. J. Thromb. Haemost. 2011; 9: 110-10.
-
(2011)
J. Thromb. Haemost.
, vol.9
, pp. 110-110
-
-
Van Ryn, J.1
Litzenburger, T.2
Waterman, A.3
-
35
-
-
84878460192
-
A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa
-
Lu GM, DeGuzman FR, Hollenbach SJ etal. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat. Med. 2013; 19: 446-451.
-
(2013)
Nat. Med.
, vol.19
, pp. 446-451
-
-
Lu, G.M.1
DeGuzman, F.R.2
Hollenbach, S.J.3
-
36
-
-
75549083726
-
Effect of recombinant activated factor VII in critical bleeding: clinical experience of a single center
-
Sartori MT, Imbergamo S, Zanon E etal. Effect of recombinant activated factor VII in critical bleeding: clinical experience of a single center. Clin. Appl. Thromb. Hemost 2009; 15: 628-635.
-
(2009)
Clin. Appl. Thromb. Hemost
, vol.15
, pp. 628-635
-
-
Sartori, M.T.1
Imbergamo, S.2
Zanon, E.3
-
37
-
-
0017252003
-
Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies
-
Smith TW, Haber E, Yeatman L, Butlern VP Jr. Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies. N. Engl. J. Med. 1976; 294: 797-800.
-
(1976)
N. Engl. J. Med.
, vol.294
, pp. 797-800
-
-
Smith, T.W.1
Haber, E.2
Yeatman, L.3
Jr Butlern, V.P.4
-
38
-
-
84876684507
-
In vitro characterization, pharmacokinetics and reversal of supratherapeutic doses of dabigatran-induced bleeding in rats by a specific antibody fragment antidote to dabigatran
-
van Ryn J, Litzenburger T, Gan GF, Coble K, Schurer J. In vitro characterization, pharmacokinetics and reversal of supratherapeutic doses of dabigatran-induced bleeding in rats by a specific antibody fragment antidote to dabigatran. Blood 2012; 120: 3418.
-
(2012)
Blood
, vol.120
, pp. 3418
-
-
van Ryn, J.1
Litzenburger, T.2
Gan, G.F.3
Coble, K.4
Schurer, J.5
-
39
-
-
84889688116
-
-
PHARMAC. [Cited 29 Oct 2013.] Available from
-
PHARMAC. [Cited 29 Oct 2013.] Available from URL: http://www.pharmac.govt.nz/2011/06/10/dabigatran%20bleeding%20management.pdf
-
-
-
-
40
-
-
84889662394
-
-
Medication Safety, Medicines Regulation and Quality and the Anticoagulant Working Party. Guideline for managing patients on Dabigatran (Pradaxa®). [Cited 29 Oct 2013.] Available from
-
Medication Safety, Medicines Regulation and Quality and the Anticoagulant Working Party. Guideline for managing patients on Dabigatran (Pradaxa®). [Cited 29 Oct 2013.] Available from URL: http://www.health.qld.gov.au/qhcss/mapsu/documents/dabigatran_info.pdf
-
-
-
-
41
-
-
84889642333
-
-
Medication Safety, Medicines Regulation and Quality and the Anticoagulant Working Party. Guideline for managing patients on Rivaroxaban (Xarelto®). [Cited 29 Oct 2013.] Available from URL:
-
Medication Safety, Medicines Regulation and Quality and the Anticoagulant Working Party. Guideline for managing patients on Rivaroxaban (Xarelto®). [Cited 29 Oct 2013.] Available from URL: http://www.health.qld.gov.au/qhcss/mapsu/documents/rivaroxaban-guideline.pdf
-
-
-
-
42
-
-
84884512133
-
Dabigatran versus warfarin in patients with mechanical heart valves
-
Eikelboom JW, Connolly SJ, Brueckmann M etal. Dabigatran versus warfarin in patients with mechanical heart valves. N. Engl. J. Med. 2013; 369: 1206-1214.
-
(2013)
N. Engl. J. Med.
, vol.369
, pp. 1206-1214
-
-
Eikelboom, J.W.1
Connolly, S.J.2
Brueckmann, M.3
|